Roche joins the CDH17 party

CDH17 antibody-drug conjugates have drawn considerable attention over the past year, with the number of assets in clinical development steadily increasing, and doubling compared with the start of the year, according to OncologyPipeline. One of these assets belongs to Hansoh Pharma, which has just licensed it Roche. The deal grants the Swiss company ex-China rights to Hansoh’s CDH-17-targeting ADC HS-20110 for $80m up front plus additional milestone payments. HS-20110, which uses a topoisomerase inhibitor as a payload, is being evaluated clinically in a phase 1 study in colorectal cancer and other solid tumours in the US and China. The agreement adds to a growing list of partnerships featuring CDH17-directed ADCs, including those between Arrivent and Lepu, Biocytogen and Sotio, and, notably, Duality Biologics and GSK. Interestingly, the latter chose to license Duality’s CDH17-targeting ADC DB-1324 rather than Hansoh’s HS-20110, despite having already struck two separate deals with Hansoh. Those earlier tie-ups concern the B7-H3-targeting ADC risvutatug rezetecan, and the anti-B7-H4 ADC mocertatug rezetecan. 

Notable Hansoh ADC deals

Source: OncologyPipeline.